Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression.

Hughes RM, Simons BW, Khan H, Miller R, Kugler V, Torquato S, Theodros D, Haffner MC, Lotan TL, Huang J, Davicioni E, An SS, Riddle RC, Thorek DL, Garraway IP, Fertig EJ, Isaacs JT, Brennen WN, Park BH, Hurley PJ.

Cancer Res. 2019 May 23. pii: canres.2931.2018. doi: 10.1158/0008-5472.CAN-18-2931. [Epub ahead of print]

PMID:
31123087
2.

In Reply.

Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR.

Stem Cells Transl Med. 2019 Jul;8(7):739-740. doi: 10.1002/sctm.19-0068. Epub 2019 Mar 29. No abstract available.

3.

Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer.

Akinboye ES, Brennen WN, Denmeade SR, Isaacs JT.

Asian J Urol. 2019 Jan;6(1):99-108. doi: 10.1016/j.ajur.2018.11.004. Epub 2018 Nov 28. Review.

4.

A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer.

Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR.

Stem Cells Transl Med. 2019 May;8(5):441-449. doi: 10.1002/sctm.18-0230. Epub 2019 Feb 8.

5.

Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?

Krueger TE, Thorek DLJ, Meeker AK, Isaacs JT, Brennen WN.

Prostate. 2019 Feb;79(3):320-330. doi: 10.1002/pros.23738. Epub 2018 Nov 28.

6.

Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Brennen WN, Isaacs JT.

Nat Rev Urol. 2018 Nov;15(11):703-715. doi: 10.1038/s41585-018-0087-9. Review.

PMID:
30214054
7.

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E.

Prostate. 2018 Dec;78(16):1262-1282. doi: 10.1002/pros.23701. Epub 2018 Aug 2.

PMID:
30073676
8.

Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise.

Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN.

Stem Cells Transl Med. 2018 Sep;7(9):651-663. doi: 10.1002/sctm.18-0024. Epub 2018 Aug 1. Review.

9.

PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer.

Rogers OC, Anthony L, Rosen DM, Brennen WN, Denmeade SR.

Oncotarget. 2018 Apr 27;9(32):22436-22450. doi: 10.18632/oncotarget.25091. eCollection 2018 Apr 27.

10.

Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer.

Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, Brennen WN, Marchionni L, Halushka MK, Lupold SE.

Sci Rep. 2018 May 8;8(1):7189. doi: 10.1038/s41598-018-25320-z.

11.

PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.

Kostova MB, Brennen WN, Lopez D, Anthony L, Wang H, Platz E, Denmeade SR.

Prostate. 2018 Aug;78(11):819-829. doi: 10.1002/pros.23539. Epub 2018 Apr 16.

PMID:
29659051
12.

The what, when, and why of human prostate cancer xenografts.

Brennen WN, Isaacs JT.

Prostate. 2018 Jun;78(9):646-654. doi: 10.1002/pros.23510. Epub 2018 Mar 24. Review.

PMID:
29575112
13.

Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy.

Brennen WN, Isaacs JT.

Cancer Cell. 2017 Oct 9;32(4):399-401. doi: 10.1016/j.ccell.2017.09.011.

14.

Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer.

Isaacs JT, Brennen WN, Denmeade SR.

Cell Cycle. 2017 Sep 17;16(18):1639-1640. doi: 10.1080/15384101.2017.1360645. Epub 2017 Aug 18. No abstract available.

15.

Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate.

Brennen WN, Zhang B, Kulac I, Kisteman LN, Antony L, Wang H, Meeker AK, De Marzo AM, Garraway IP, Denmeade SR, Isaacs JT.

Oncotarget. 2017 Jul 18;8(29):46710-46727. doi: 10.18632/oncotarget.17362.

16.

Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay.

Brennen WN, Nguyen H, Dalrymple SL, Reppert-Gerber S, Kim J, Isaacs JT, Hammers H.

Oncotarget. 2016 Nov 1;7(44):71298-71308. doi: 10.18632/oncotarget.11347.

17.

A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.

Levy O, Brennen WN, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani SH, Joshi N, Bhowmick N, Denmeade SR, Isaacs JT, Karp JM.

Biomaterials. 2016 Jun;91:140-150. doi: 10.1016/j.biomaterials.2016.03.023. Epub 2016 Mar 17.

18.

Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.

Akinboye ES, Brennen WN, Rosen DM, Bakare O, Denmeade SR.

Prostate. 2016 Jun;76(8):703-14. doi: 10.1002/pros.23162. Epub 2016 Feb 2.

19.

Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures.

Brennen WN, Kisteman LN, Isaacs JT.

Prostate. 2016 May;76(6):552-64. doi: 10.1002/pros.23145. Epub 2016 Jan 6.

20.

Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug Therapy.

Miles LA, Brennen WN, Rudin CM, Poirier JT.

PLoS One. 2015 Aug 19;10(8):e0136480. doi: 10.1371/journal.pone.0136480. eCollection 2015. No abstract available.

21.

Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy.

Miles LA, Brennen WN, Rudin CM, Poirier JT.

PLoS One. 2015 Jun 12;10(6):e0129103. doi: 10.1371/journal.pone.0129103. eCollection 2015. Erratum in: PLoS One. 2015;10(8):e0136480.

22.

Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.

Brennen WN, Rosen DM, Chaux A, Netto GJ, Isaacs JT, Denmeade SR.

Prostate. 2014 Sep;74(13):1308-19. doi: 10.1002/pros.22847. Epub 2014 Jul 22.

23.

Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer.

Brennen WN, Drake CG, Isaacs JT.

Cancer Res. 2014 Jul 1;74(13):3390-5. doi: 10.1158/0008-5472.CAN-14-0249. Epub 2014 Apr 18.

24.

Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment.

Brennen WN, Denmeade SR, Isaacs JT.

Endocr Relat Cancer. 2013 Aug 23;20(5):R269-90. doi: 10.1530/ERC-13-0151. Print 2013 Oct. Review.

25.

Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer.

Brennen WN, Chen S, Denmeade SR, Isaacs JT.

Oncotarget. 2013 Jan;4(1):106-17.

26.

Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.

Isaacs JT, Antony L, Dalrymple SL, Brennen WN, Gerber S, Hammers H, Wissing M, Kachhap S, Luo J, Xing L, Björk P, Olsson A, Björk A, Leanderson T.

Cancer Res. 2013 Feb 15;73(4):1386-99. doi: 10.1158/0008-5472.CAN-12-2730. Epub 2012 Nov 13.

27.

Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.

Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR.

J Natl Cancer Inst. 2012 Sep 5;104(17):1320-34. doi: 10.1093/jnci/djs336. Epub 2012 Aug 21.

28.

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.

Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, Isaacs JT.

Sci Transl Med. 2012 Jun 27;4(140):140ra86. doi: 10.1126/scitranslmed.3003886. Erratum in: Sci Transl Med. 2012 Jul 18;4(143):143er4.

29.

Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy.

Brennen WN, Isaacs JT, Denmeade SR.

Mol Cancer Ther. 2012 Feb;11(2):257-66. doi: 10.1158/1535-7163.MCT-11-0340. Review.

30.

Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.

Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, Britton J, Kachhap SK, Shim JS, Liu JO, Nelson WG, Yegnasubramanian S, Carducci MA.

Prostate. 2011 Mar 1;71(4):333-43. doi: 10.1002/pros.21247. Epub 2010 Aug 31.

31.

Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin.

LeBeau AM, Brennen WN, Aggarwal S, Denmeade SR.

Mol Cancer Ther. 2009 May;8(5):1378-86. doi: 10.1158/1535-7163.MCT-08-1170. Epub 2009 May 5.

32.

Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites.

Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, Cotter RJ, Denmeade SR.

Biochemistry. 2008 Jan 22;47(3):1076-86. Epub 2007 Dec 21.

33.

Thalidomide and analogues: current proposed mechanisms and therapeutic usage.

Brennen WN, Cooper CR, Capitosti S, Brown ML, Sikes RA.

Clin Prostate Cancer. 2004 Jun;3(1):54-61. Review.

PMID:
15279692
34.

Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers.

Sikes RA, Walls AM, Brennen WN, Anderson JD, Choudhury-Mukherjee I, Schenck HA, Brown ML.

Clin Prostate Cancer. 2003 Dec;2(3):181-7. Review.

PMID:
15040863

Supplemental Content

Loading ...
Support Center